Faculty Profiles - FUJIWARA Toshiyoshi

Papers - FUJIWARA Toshiyoshi

Division display 261 - 280 of about 1,586 ／ All the affair displays >>

ロボット支援下食道切除術のエビデンスわれわれのロボット支援食道切除術定型化の変遷

白川靖博, 桂佑貴, 井谷史嗣, 松川啓義, 橋本将志, 加藤卓也, 前田直見, 田辺俊介, 野間和広, 藤原俊義

日本食道学会学術集会プログラム・抄録集 77回 7 - 7 2023.6

ロボット支援下食道切除術のエビデンスロボット支援化食道切除180例の検討定型化とNIM導入の短期成績とその課題

野間和広, 河崎健人, 國友知義, 橋本将志, 賀島肇, 加藤卓也, 前田直見, 菊地覚次, 田辺俊介, 白川靖博, 藤原俊義

日本食道学会学術集会プログラム・抄録集 77回 7 - 7 2023.6

cT4食道癌に対する根治を目指した治療戦略

前田直見, 野間和広, 河崎健人, 國友知義, 橋本将志, 賀島肇, 加藤卓也, 菊地覚次, 田辺俊介, 白川靖博, 藤原俊義

日本食道学会学術集会プログラム・抄録集 77回 134 - 134 2023.6

高齢者食道癌患者に対する根治的手術戦略

河崎健人, 野間和広, 國友知義, 橋本将志, 賀島肇, 加藤卓也, 前田直見, 菊地覚次, 田辺俊介, 白川靖博, 藤原俊義

日本食道学会学術集会プログラム・抄録集 77回 169 - 169 2023.6

滑脱型食道裂孔ヘルニアを伴う胃噴門部粘膜下腫瘍に対してLECSが有用であった1例

賀島肇, 野間和広, 半澤俊哉, 河崎健人, 國友知義, 橋本将志, 加藤卓也, 前田直見, 菊地覚次, 田辺俊介, 藤原俊義

日本食道学会学術集会プログラム・抄録集 77回 231 - 231 2023.6

食道がん術後患者のQOL向上に向けた多職種、施設間連携の強化と介入の仕組みづくり

山本有美, 野間和広, 青井美由紀, 川上雅弘, 橋本将志, 加藤卓也, 前田直見, 田辺俊介, 白川靖博, 藤原俊義

日本食道学会学術集会プログラム・抄録集 77回 259 - 259 2023.6

形成外科医による縦隔気管孔作成安全かつ低侵襲なTangentially sternal osteotomy

松本洋, 太田智之, 木股敬裕, 野間和広, 田辺俊介, 前田直見, 橋本将志, 加藤卓也, 藤原俊義, 白川靖博

日本食道学会学術集会プログラム・抄録集 77回 265 - 265 2023.6

逆流防止機構を備えたDouble Flap Techniqueの挑戦

加藤卓也, 野間和広, 河崎健人, 國友知義, 橋本将志, 賀島肇, 前田直見, 菊地覚次, 田辺俊介, 白川靖博, 藤原俊義

日本食道学会学術集会プログラム・抄録集 77回 327 - 327 2023.6

cStage II/IIIA食道癌:DCF NAC後の術後補助療法とその適応 pN2以上の再発リスクに対する術後補助免疫療法の短期成績

橋本将志, 野間和広, 河崎健人, 國友知義, 賀島肇, 加藤卓也, 前田直見, 菊地覚次, 田辺俊介, 白川靖博, 藤原俊義

日本食道学会学術集会プログラム・抄録集 77回 45 - 45 2023.6

巨大食道裂孔ヘルニアに対する治療の工夫と成績巨大食道裂孔ヘルニアの腹腔鏡根治術における再発軽減のための手術手技の工夫と成績

田辺俊介, 野間和広, 河崎健人, 國友知義, 橋本将志, 賀島肇, 加藤卓也, 前田直見, 菊地覚次, 白川靖博, 藤原俊義

日本食道学会学術集会プログラム・抄録集 77回 60 - 60 2023.6

当院におけるJz癌に対するoptimum surgical approach strategy

桂佑貴, 白川靖博, 石田道拡, 丁田泰宏, 井谷史嗣, 松川啓義, 塩崎滋弘, 田邊俊介, 野間和広, 藤原俊義

日本食道学会学術集会プログラム・抄録集 77回 93 - 93 2023.6

食道癌根治切除時における再建経路がQOLに与える影響についての比較

國友知義, 野間和広, 川崎健人, 橋本将志, 賀島肇, 加藤卓也, 前田直見, 菊地覚次, 田辺俊介, 白川靖博, 藤原俊義

日本食道学会学術集会プログラム・抄録集 77回 125 - 125 2023.6

Conventional Cancer Therapies Can Accelerate Malignant Potential of Cancer Cells by Activating Cancer-Associated Fibroblasts in Esophageal Cancer Models. Reviewed International journal

Satoshi Komoto, Kazuhiro Noma, Takuya Kato, Teruki Kobayashi, Noriyuki Nishiwaki, Toru Narusaka, Hiroaki Sato, Yuki Katsura, Hajime Kashima, Satoru Kikuchi, Toshiaki Ohara, Hiroshi Tazawa, Toshiyoshi Fujiwara

Cancers 15 ( 11 ) 2023.5

Language：English Publishing type：Research paper (scientific journal)

Esophageal cancer is one of the most aggressive tumors, and the outcome remains poor. One contributing factor is the presence of tumors that are less responsive or have increased malignancy when treated with conventional chemotherapy, radiotherapy, or a combination of these. Cancer-associated fibroblasts (CAFs) play an important role in the tumor microenvironment. Focusing on conventional cancer therapies, we investigated how CAFs acquire therapeutic resistance and how they affect tumor malignancy. In this study, low-dose chemotherapy or radiotherapy-induced normal fibroblasts showed enhanced activation of CAFs markers, fibroblast activation protein, and α-smooth muscle actin, indicating the acquisition of malignancy in fibroblasts. Furthermore, CAFs activated by radiotherapy induce phenotypic changes in cancer cells, increasing their proliferation, migration, and invasion abilities. In in vivo peritoneal dissemination models, the total number of tumor nodules in the abdominal cavity was significantly increased in the co-inoculation group of cancer cells and resistant fibroblasts compared to that in the co-inoculation group of cancer cells and normal fibroblasts. In conclusion, we demonstrated that conventional cancer therapy causes anti-therapeutic effects via the activation of fibroblasts, resulting in CAFs. It is important to select or combine modalities of esophageal cancer treatment, recognizing that inappropriate radiotherapy and chemotherapy can lead to resistance in CAF-rich tumors.

DOI： 10.3390/cancers15112971

PubMed

researchmap

Impact of sarcopenia on clinical outcomes for patients with resected hepatocellular carcinoma: A retrospective comparison of eastern and western cohorts. Reviewed International journal

Berend Robert Beumer, Kosei Takagi, Stefan Buettner, Yuzo Umeda, Takahito Yagi, Toshiyoshi Fujiwara, Jeroen Laurens Ad van Vugt, Jan Nicolas Maria IJzermans

International journal of surgery (London, England) 109 ( 8 ) 2258 - 2266 2023.5

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Patient fitness is important for guiding treatment. Muscle mass, as a reflection thereof, can be objectively measured. However, the role of east-west differences remains unclear. Therefore, we compared the impact of muscle mass on clinical outcomes after liver resection for HCC in a Dutch (NL) and Japanese (JP) setting and evaluated the predictive performance of different cut-off values for sarcopenia. METHOD: In this multicenter retrospective cohort study patients with hepatocellular carcinoma (HCC) undergoing liver resection were included. The skeletal muscle mass index (SMI) was determined on CT scans obtained within 3 months before surgery. The primary outcome measure was overall survival (OS). Secondary outcome measures were: 90-day mortality, severe complications, length of stay, and recurrence free survival. The predictive performance of several sarcopenia cut-off values was studied using the c-index and area under the curve. Interaction terms were used to study geographic effect modification of muscle mass. RESULTS: Demographics differed between NL and JP. Gender, age, and body mass index were associated with SMI. Significant effect modification between NL and JP was found for BMI. The predictive performance of sarcopenia for both short- and long-term outcomes was higher in JP compared to NL (max c-index: 0.58 vs 0.55, respectively). However, differences between cut-off values were small. For the association between sarcopenia and OS, a strong association was found in JP (Hazard ratio (HR) 2.00 95%CI[1.230 ; 3.08], P=0.002), where this was not found in NL (0.76 [0.42 ; 1.36], P=0.351). The interaction term confirmed that this difference was significant (HR 0.37 95%CI[0.19 ; 0.73], P=0.005). CONCLUSIONS: The impact of sarcopenia on survival differs between the east and west. Clinical trials and treatment guidelines using sarcopenia for risk stratification should be validated in race-dependent populations prior to clinical adoption.

DOI： 10.1097/JS9.0000000000000458

PubMed

researchmap

Clinical implications and optimal extent of lymphadenectomy for intrahepatic cholangiocarcinoma: A multicenter analysis of the therapeutic index. Reviewed

Yuzo Umeda, Kosei Takagi, Tatsuo Matsuda, Tomokazu Fuji, Toru Kojima, Daisuke Satoh, Masayoshi Hioki, Yoshikatsu Endo, Masaru Inagaki, Masahiro Oishi, Takahito Yagi, Toshiyoshi Fujiwara

Annals of gastroenterological surgery 7 ( 3 ) 512 - 522 2023.5

Language：English Publishing type：Research paper (scientific journal)

AIMS: Lymph node metastases (LNM) are associated with lethal prognosis in intrahepatic cholangiocarcinoma (ICC). Lymphadenectomy is crucial for accurate staging and hopes of possible oncological treatment. However, the therapeutic implications and optimal extent of lymphadenectomy remain contentious. METHODS: To clarify the prognostic value and optimal extent of lymphadenectomy, the therapeutic index (TI) for each lymph node was analyzed for 279 cases that had undergone lymphadenectomy in a multi-institutional database. Tumor localization was divided into hilar lesions (n = 130), right peripheral lesions (n = 60), and left peripheral lesions (n = 89). In addition, the lymph node station was classified as Level 1 (LV1: hepatoduodenal ligament node), Level 2 (LV2: postpancreatic or common hepatic artery nodes), or Level 3 (LV3: gastrocardiac, left gastric artery, or celiac artery nodes). RESULTS: Lymph node metastases were confirmed in 109 patients (39%). Five-y survival rates were 45.3% for N0 disease, 27.1% for LV1-LNM, 22.9% for LV2-LNM, and 7.3% for LV3-LNM (P < 0.001). LV3-LNM were the most frequent and earliest recurrence outcome, including multisite recurrence, followed by LV2, LV1, and N0 disease. The 5-year TI (5year-TI) for lymphadenectomy was 7.2 for LV1, 5.5 for LV2, and 1.9 for LV3. Regarding tumor location, hilar lesions showed 5-year TI >5.0 in LV1 and LV2, whereas bilateral peripheral lesions showed 5-year TI > 5.0 in LV1. CONCLUSION: The implications and extent of lymphadenectomy for ICC appear to rely on tumor location. In the peripheral type, the benefit of lymphadenectomy would be limited and dissection beyond LV1 should be avoided, while in the hilar type, lymphadenectomy up to LV2 could be recommended.

DOI： 10.1002/ags3.12642

PubMed

researchmap

【イラストで見る消化器癌手術アトラス】食道・胃ロボット支援下食道切除術における標準化と手技の工夫

野間和広, 田辺俊介, 前田直見, 藤原俊義

手術 77 ( 6 ) 757 - 762 2023.5

【消化器外科における各種デバイスの使い方とピットフォール】上部消化管食道・胃切除術における自動縫合器の使い方とピットフォール

田邊俊介, 垣内慶彦, 前田直見, 菊地覚次, 黒田新士, 野間和広, 藤原俊義

外科 85 ( 4 ) 345 - 350 2023.4

Language：Japanese Publisher：(株)南江堂

＜文献概要＞近年,自動縫合器を使用した臓器の切離,および再建が普及している.一方で,従来行われていた手縫い吻合と異なり,各臓器において使用の際のピットフォールが存在すると思われる.今回,当科で行っている食道および胃切除術時のサーキュラーステープラおよびリニアステープラの使い方およびそのピットフォールを説明する.

researchmap

Other Link： https://search.jamas.or.jp/default/link?pub_year=2023&ichushi_jid=J00393&link_issn=&doc_id=20230414270006&doc_link_id=10.15106%2Fj_geka85_345&url=https%3A%2F%2Fdoi.org%2F10.15106%2Fj_geka85_345&type=%E5%8C%BB%E6%9B%B8.jp_%E3%82%AA%E3%83%BC%E3%83%AB%E3%82%A2%E3%82%AF%E3%82%BB%E3%82%B9&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

食道癌術前化学療法時から介入する多職種チーム医療と微量元素に着目した栄養管理

田辺俊介, 野間和広, 橋本将志, 前田直見, 重安邦俊, 菊地覚次, 黒田新士, 近藤喜太, 吉田龍一, 櫻間教文, 寺石文則, 楳田祐三, 白川靖博, 藤原俊義

日本外科学会定期学術集会抄録集 123回 DP - 6 2023.4

食道良性疾患に対する手術の限界と挑戦高齢者に対する食道裂孔ヘルニアの腹腔鏡根治術における現状と手技の工夫

藤田脩斗, 野間和広, 橋本将志, 前田直見, 菊地覚次, 重安邦俊, 黒田新士, 近藤喜太, 田辺俊介, 吉田龍一, 寺石文則, 楳田祐三, 白川靖博, 藤原俊義

日本外科学会定期学術集会抄録集 123回 WS - 6 2023.4

ロボット手術と多科合同手術で食道癌に挑む

門脇大輔, 野間和広, 橋本将志, 前田直見, 重安邦俊, 菊地覚次, 近藤喜太, 黒田新士, 田辺俊介, 吉田龍一, 寺石文則, 楳田祐三, 白川靖博, 藤原俊義

日本外科学会定期学術集会抄録集 123回 DP - 5 2023.4

　 PREV - NEXT 　

< FUJIWARA Toshiyoshi >

Papers - FUJIWARA Toshiyoshi